In the published article, there was an error in Figure 7B as published. The graph in Figure 7B was identical to Figure 7A, and has been replaced with the correct version. The corrected Figure 7B and its caption “FIGURE 7: In vivo immunogenicity of xenogeneic hAF and allogeneic rAF in rats. Detection of (A) anti-hAF or (B) anti-rAF antibodies by ELISA coated with hAF or rAF extracts, respectively. Control: serum from rats treated with PBS. Background: no serum. Data are presented as mean ± SD by OD at 450 nm for each serum concentration (n = 6/group).” appear below.
FIGURE 7
The original version of this article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
adipose tissue, adipose stem cells, tissue engineering, MASLD, fibrosis, inflammation
Citation
Choi Y, Ma Y, Tom S, Danilkovitch A and Yu L (2025) Correction: An engineered adipose formulation decreases hepatic inflammation and fibrosis in a rodent model of metabolic dysfunction-associated steatotic liver disease. Front. Bioeng. Biotechnol. 13:1642526. doi: 10.3389/fbioe.2025.1642526
Received
06 June 2025
Accepted
18 June 2025
Published
26 June 2025
Volume
13 - 2025
Edited and reviewed by
Luca Urbani, Foundation for Liver Research, United Kingdom
Updates
Copyright
© 2025 Choi, Ma, Tom, Danilkovitch and Yu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alla Danilkovitch, adanilkovitch@britecyte.com; Liqing Yu, lyu@som.umaryland.edu
† These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.